IGFBP2 silencing counteracted gefitinib-increased VEGFR expression in NSCLC cells, thus inhibiting the nuclear translocation of activated STAT3, suggesting that IGFBP2 contributes to gefitinib resistance via VEGFR/STAT3 signaling. Here, KDR is linked to non-small cell lung carcinoma.